ICU · toxicology
Acute Snake Envenomation — Comprehensive (ANZ Context)
Also known as Snakebite envenomation · Snake envenoming · Elapid envenomation · Brown snake bite · Tiger snake bite · Taipan bite · Death adder bite · Venom-induced consumption coagulopathy · VICC · Australian snakebite · Pressure immobilisation bandage · Snake antivenom
Acute snake envenomation in Australia and New Zealand — the world's most venomous snakes belong to the family Elapidae (front-fanged: brown snake [Pseudonaja — 1 cause of snakebite death — procoagulant + presynaptic neurotoxin + rarely thrombotic microangiopathy], tiger snake [Notechis — procoagulant + neurotoxic + myotoxic], taipan [Oxyuranus — most toxic land snake — procoagulant + neurotoxic + myotoxic], death adder [Acanthophis — postsynaptic neurotoxin — curare-like; mechanistically reversible but ASP cohort showed no reversal by antivenom (median resolution 21 h)], black snake [Pseudechis — myotoxic + anticoagulant], rough-scaled snake [Tropidechis — procoagulant + myotoxic], sea snakes [Hydrophiidae — myotoxic + neurotoxic]). Clinical syndromes: (1) PROCOAGULANT → venom-induced consumption coagulopathy [VICC] — prothrombin activators → massive consumption of fibrinogen and factors V, VIII, X → INR 5 + fibrinogen <0.5 + D-dimer massively elevated + PLATELETS NORMAL — but BLEEDING IS RARE despite extreme coagulopathy because the venom clots AND lyses simultaneously (unlike warfarin or DIC — no true anticoagulated state) — give antivenom NOT FFP unless actively bleeding — recovery takes 24-36 h as the liver resynthesises factors (ASP-10). (2) NEUROTOXIC → descending flaccid paralysis: ptosis → ophthalmoplegia → bulbar palsy → limb weakness → respiratory failure — resembles myasthenia gravis (postsynaptic: death adder) or botulism (presynaptic: tiger, brown, taipan) — the pupil reflex and deep tendon reflexes distinguish. (3) MYOTOXIC → muscle pain, tenderness, rising CK (10,000-100,000+), myoglobinuria, AKI — tiger, black, taipan, sea snakes. (4) NEPHROTOXIC → AKI from rhabdomyolysis + direct nephrotoxicity + thrombotic microangiopathy — brown snake. (5) CARDIOVASCULAR COLLAPSE → sudden early collapse (within 1h of bite) — brown snake — thought to be transient hypotension from venom cardiotoxicity or anaphylactoid reaction — high-risk feature. Management: (1) FIRST AID: pressure immobilisation bandage [PIB] — broad bandage over bite site + splint + immobilise the limb — slows LYMPHATIC venom spread (NOT venous — venom moves via lymphatics) — DO NOT remove until antivenom ready in hospital (removal causes venom surge). (2) SNAKE VENOM DETECTION KIT [SVDK] — bite site swab or urine — identifies snake GROUP (brown, tiger, black, death adder, taipan) — guides monovalent antivenom choice — BUT 5% false negative in envenomed patients + 36% false positive in non-envenomed patients — clinical syndromic diagnosis is more reliable. (3) ANTIVENOM: monovalent if snake identified by SVDK or clinical/geographic assessment OR polyvalent if snake unknown — ONE VIAL is sufficient to bind all circulating venom (recent evidence: median dose declined from 4 to 1 vial without harm) — pre-medicate with adrenaline (subcutaneous 0.25 mg) to reduce hypersensitivity reactions (24% reaction rate, 6% severe) — large volumes if polyvalent (dilute in crystalloid, infuse over 30 min). (4) VICC MANAGEMENT: give antivenom — DO NOT give blood products (FFP, cryoprecipitate, platelets) UNLESS actively bleeding — the coagulopathy resolves within 24-36 h as the liver resynthesises factors (ASP-10) — giving FFP 'feeds' the venom prothrombin activator more substrate to consume (paradoxical worsening) and risks transfusion reactions. (5) SUPPORTIVE: mechanical ventilation for neurotoxicity, renal replacement therapy for AKI, treat rhabdomyolysis with fluids. Mortality ~1-2% with antivenom (23 deaths over 10 years in ASP-20; 17 from brown snake).
Checked against its sources on 2 Sept 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- BLEEDING IS RARE in VICC despite INR >10 and unrecordable fibrinogen — the venom simultaneously activates prothrombin (consumes factors) AND activates plasminogen (lyses clot) — there is NO true anticoagulated state — do NOT give FFP/cryoprecipitate/platelets unless the patient is ACTIVELY bleeding — the coagulopathy resolves within 24-36 h irrespective of snake type (ASP-10, ref 18)
- DO NOT remove the pressure immobilisation bandage until antivenom is ready and IV access established — removal causes a sudden surge of venom into the circulation ('bolus effect') — can precipitate cardiovascular collapse
- SVDK has a 36% FALSE POSITIVE rate in non-envenomed patients and a 4.9% WRONG-VENOM rate in envenomed patients with a confirmed snake type (the kit detects venom but names the wrong immunotype) — NEVER use SVDK alone to decide on antivenom — diagnose envenoming on CLINICAL and LABORATORY evidence (VICC, neurotoxicity, myotoxicity, collapse)
- Sudden early collapse (within 1h of brown snake bite) is a HIGH-RISK feature — indicates severe envenoming — cardiovascular collapse may be transient but signals risk of cardiac arrest — treat as an emergency and prepare antivenom immediately
- Neurotoxicity from presynaptic toxins (tiger, brown, taipan) is NOT reversible by antivenom once established — antivenom prevents further toxin binding but does NOT reverse already-damaged nerve terminals — early antivenom and prolonged ventilation (days) required — contrast with death adder (postsynaptic — mechanistically reversible; anecdotally responds to anticholinesterase, though the ASP cohort found neurotoxicity not reversed by antivenom, median resolution 21 h)
- Thrombotic microangiopathy (brown snake) — 13% of brown snake VICC cases — presents with severe thrombocytopenia (<20), MAHA, AKI requiring dialysis at 1-3 days post-bite — NOT the same as VICC — platelets ARE low (unlike simple VICC where platelets are normal) — supportive care including dialysis, role of plasma exchange uncertain
Meet the patient
A 42-year-old man collapses after a suspected brown snake bite in rural NSW. He arrives alert, BP 95 over 55 after fluids, no active bleeding, INR over 10, fibrinogen unrecordable, D-dimer over 20, platelets 185, CK 220. The pressure immobilisation bandage is still on.[1]
Two questions decide every snakebite: is the patient actually envenomed? (diagnose on the clinical syndrome and labs — never on the SVDK alone), and have I left the bandage on until the antivenom is drawn up? (removal releases a venom bolus). Hold those two and the rest follows.[2]
References18ShowHide
- [1]Isbister GK, Brown SG, Page CB, et al. Snakebite in Australia: a practical approach to diagnosis and treatment Med J Aust, 2013.PMID 24329653
- [2]Johnston CI, Ryan NM, Page CB, et al. The Australian Snakebite Project, 2005-2015 (ASP-20) Med J Aust, 2017.PMID 28764620
- [3]Isbister GK, Duffull SB, Brown SG; ASP Investigators. Failure of antivenom to improve recovery in Australian snakebite coagulopathy QJM, 2009.PMID 19570990
- [4]Cheng AC, Currie BJ. Venomous snakebites worldwide with a focus on the Australia-Pacific region: current management and controversies J Intensive Care Med, 2004.PMID 15358944
- [5]Isbister GK, Little M, Cull G, et al. Thrombotic microangiopathy from Australian brown snake (Pseudonaja) envenoming Intern Med J, 2007.PMID 17640187
- [6]Isbister GK, Jayamanne S, Mohamed F, et al. A randomized controlled trial of fresh frozen plasma for coagulopathy in Russell's viper (Daboia russelii) envenoming J Thromb Haemost, 2017.PMID 28106331
- [7]Maduwage K, Isbister GK. Current treatment for venom-induced consumption coagulopathy resulting from snakebite PLoS Negl Trop Dis, 2014.PMID 25340841
- [8]Isbister GK. Snakebite doesn't cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming Semin Thromb Hemost, 2010.PMID 20614396
- [9]Rodrigo C, Gnanathasan A. Adjunct treatment in snakebite envenoming: a systematic review of randomised controlled trials Trans R Soc Trop Med Hyg, 2020.PMID 32780827
- [10]de Silva HA, Ryan NM, de Silva HJ. Adverse reactions to snake antivenom, and their prevention and treatment Br J Clin Pharmacol, 2016.PMID 26256124
- [11]Ryan NM, Kearney RT, Brown SG, Isbister GK. Incidence of serum sickness after the administration of Australian snake antivenom (ASP-22) Clin Toxicol (Phila), 2016.PMID 26490786
- [12]Ryan NM, Downes MA, Isbister GK. Clinical features of serum sickness after Australian snake antivenom Toxicon, 2015.PMID 26525657
- [13]Currie B, Fitzmaurice M, Oakley J. Resolution of neurotoxicity with anticholinesterase therapy in death-adder envenomation Med J Aust, 1988.PMID 3367819
- [14]Johnston CI, O'Leary MA, Brown SG, et al. Death adder envenoming causes neurotoxicity not reversed by antivenom — Australian Snakebite Project (ASP-16) PLoS Negl Trop Dis, 2012.PMID 23029595
- [15]Johnston CI, Isbister GK. Australian snakebite myotoxicity (ASP-23) Clin Toxicol (Phila), 2021.PMID 33156703
- [16]Gan M, O'Leary MA, Brown SG, et al. Envenoming by the rough-scaled snake (Tropidechis carinatus): a series of confirmed cases Med J Aust, 2009.PMID 19645653
- [17]Silva A, Hodgson WC, Isbister GK. Antivenom for neuromuscular paralysis resulting from snake envenoming Toxins (Basel), 2017.PMID 28422078
- [18]Isbister GK, Scorgie FE, O'Leary MA, et al. Factor deficiencies in venom-induced consumption coagulopathy resulting from Australian elapid envenomation: Australian Snakebite Project (ASP-10) J Thromb Haemost, 2010.PMID 20831619